kabutan

Ajinomoto Co., Inc.(2802) Summary

2802
TSE Prime
Ajinomoto Co., Inc.
3,366.0
JPY
+63.0
(+1.91%)
Dec 12, 3:30 pm JST
21.60
USD
Dec 12, 1:30 am EST
Result
PTS
outside of trading hours
3,375
Dec 12, 11:31 pm JST
Summary Chart Historical News Financial Result
PER
27.1
PBR
4.55
Yield
1.43%
Margin Trading Ratio
0.93
Stock Price
Dec 12, 2025
Opening Dec 12, 9:00 am
3,368.0 JPY 21.65 USD
Previous Close Dec 11
3,303.0 JPY 21.16 USD
High Dec 12, 3:02 pm
3,386.0 JPY 21.74 USD
Low Dec 12, 9:30 am
3,335.0 JPY 21.42 USD
Volume
5,051,300
Trading Value
0.02T JPY 0.11B USD
VWAP
3365.91 JPY 21.6 USD
Minimum Trading Value
336,600 JPY 2,160 USD
Market Cap
3.38T JPY 0.02T USD
Number of Trades
6,400
Liquidity & Number of Trades
As of Dec 12, 2025
Liquidity
High
1-Year Average
4,453
1-Year High Nov 10, 2025
20,284
Margin Trading
Date Short Interest Long Margin Positions Ratio
Dec 5, 2025 112,000 2,047,000 18.28
Nov 28, 2025 117,300 1,964,100 16.74
Nov 21, 2025 96,300 1,771,500 18.40
Nov 14, 2025 144,500 1,764,300 12.21
Nov 7, 2025 294,700 1,762,300 5.98
Company Profile
Ajinomoto Co., Inc. is a leading comprehensive food company, ranking first in seasonings. The company has diversified into pharmaceuticals, animal feed, and other sectors, and is actively pursuing M&A opportunities.
Sector
Foods
Ajinomoto Co., Inc. is a comprehensive food manufacturer with a primary focus on seasonings, nutritional and processed foods, solution and ingredients, and frozen foods. The company also operates in non-food sectors, including pharmaceutical and food-grade amino acids, biopharmaceutical services (CDMO), and functional materials (such as electronic materials). With numerous subsidiaries both domestically and internationally, Ajinomoto conducts business on a global scale. The company has particularly strong business foundations in Southeast Asia and South America. In the seasoning business, Ajinomoto has local subsidiaries in Thailand, Indonesia, Vietnam, the Philippines, and Malaysia, among others. The frozen food business has also expanded into North America. Additionally, the company is focusing on strengthening its biopharmaceutical services business.